D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B5 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

EFFECT - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV). The TVGN 930 cumulative 5-year top-line revenue forecast is estimated to be ~$3.5 billion. The fo

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company's investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity in these individuals and directly eliminate the virus. The CTLs are directed against the entire viral genome rather than single protein. Publication of positive POC/dose finding clinical trial data o

WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days. Tevogen's key assets include: Intellectual Property Portfolio – Three wholly owned, granted U.S. patents and twelve pending U.S. patents, including two in artificial intelligence.Drug Development Platforms – ExacTcell™: highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH '95, and the Company's mission of health equity. In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his "vision to make healthcare more affordable and accessible" and the impact that Tevogen Bio has had on the world. Tevogen's business model is designed to withstand current market pressures through a lean, capital-efficient structure. By fully owning its core intellectual property and avoiding costly licensing overhead, the Company is

WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased 24% compared to the reported amount on March 31, 2025; this is following a 60% increase reported for the first quarter. The largest contributors to the second quarter growth were Morgan Stanley and BlackRock, which together increased their holdings by 80%. In additi

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio's Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, "Driven by an unrelenting passion to advance the cause of health equity for all and the belief that societal prosperity and business success are intrinsically linked, Saadi has tirelessly strived to pave the way

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. This formalizes the binding term sheet previously announced May 10, 2024. Combined with this financing, Tevogen's efficient and innovative business model is expected to support r

Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑esteem, and community reintegration. "This donation is a small way to express my admiration for Opportunity Project's work and its impact on so many lives," said D

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. "Tevogen is an asset-rich enterprise, and we plan on sharing a comprehensive inventory of Tevogen's wholly owned internally developed assets and their standard methodology valuation. These intangible assets are not reflected in financial reports due to US GAAP accounting rules, but they do underscore the magnitude of what we have built in such a short time. It is important for shareholders to understand that these assets, including our intellectual property portfolio, drug development

SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com

WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and supporting high-risk groups, including first responders. Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters As

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio ("Tevogen") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations. "I share Marc's belief

WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membershi

WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announces the appointment of William Keane as Vice President of Strategic Initiatives. Mr. Keane brings 35 years of leadership experience in law enforcement, having most recently served as the Chief of Police for Warren, New Jersey, for the past decade. He has also held various management positions throughout his career. He will work closely with various functional leads to ensure policies and procedures conform

WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio') (NASDAQ:TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio. Most recently, Mr. Shah was Director, Relationship Management, in Citigroup's Client organization, where he was also a member of the Executive Office. Prior to Citigroup, he worked in Morgan Stanley's asset management business (MSIM) focused on Equity Strategy and Product Development. Mr.